SCHEMBL6073385

SCHEMBL6073385

C[C@@H]1CN(c2ccc(Nc3ncc4ccc(NC(=O)NC(C)(C)C)nc4n3)cc2)C[C@H](C)N1C(=O)OC(C)(C)C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 4/20 0.40
CCND3 P30281 2/20 0.40
CCNK O75909 1/20 0.40
CCNA2 P20248 1/20 0.40
CDK2 P24941 1/20 0.40
CDK9 P50750 1/20 0.40
CDK6 Q00534 1/20 0.40
JAK3 P52333 8/20 0.39
CDK4 P11802 1/20 0.39
CCND1 P24385 1/20 0.39
CCND2 P30279 1/20 0.39
EGFR P00533 1/20 0.38
MAPT P10636 2/20 0.36
MEN1 O00255 1/20 0.36
TSHR P16473 1/20 0.36
KMT2A Q03164 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
JAK2 O60674 1/20 0.36
JAK1 P23458 1/20 0.36
TYK2 P29597 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6073388 1.00 SYK (0.40) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6074137 0.88 AURKB (0.41) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6074141 0.88 AURKB (0.41) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6073729 0.86 FGFR1 (0.46) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6073735 0.86 FGFR1 (0.46) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6073958 0.86 FGFR1 (0.41) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6073961 0.86 FGFR1 (0.41) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6074187 0.86 FGFR1 (0.41) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6074180 0.86 FGFR1 (0.41) SYKCCND3CCNKCCNA2CDK2
SCHEMBL6073911 0.86 CDK2 (0.54) SYKCCND3CCNKCCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053070-B2 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors WARNER-LAMBERT COMPANY (US) 2006-05-30 US disclosed
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors BOOTH RICHARD JOHN (US) 2003-04-17 US disclosed
EP-1254137-A1 PYRIDO 2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2002-11-06 EP disclosed
WO-2001055147-A1 PYRIDO[2,3-d]PYRIMIDINE-2,7-DIAMINE KINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073668-A1 Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors CDK9, CDK19, CDK3 SYK 1176/4885CCND3 98/4885CCNK 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.